35 related articles for article (PubMed ID: 34154314)
1. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
[TBL] [Abstract][Full Text] [Related]
2. Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas.
Torkildsen CF; Thomsen LCV; Sande RK; Krakstad C; Stefansson I; Lamark EK; Knappskog S; Bjørge L
Cancer Med; 2023 Jul; 12(13):14183-14195. PubMed ID: 37191035
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
[TBL] [Abstract][Full Text] [Related]
4. Pathological Characterization of Ovarian Cancer Patients Who Underwent Debulking Surgery in Combination With Diaphragmatic Surgery: A Cross-Sectional Study.
Nagai T; Oshiro H; Sagawa Y; Sakamaki K; Terauchi F; Nagao T
Medicine (Baltimore); 2015 Dec; 94(50):e2296. PubMed ID: 26683966
[TBL] [Abstract][Full Text] [Related]
5. Predicting incomplete cytoreduction in patients with advanced ovarian cancer.
Egger EK; Buchen MA; Recker F; Stope MB; Strunk H; Mustea A; Marinova M
Front Oncol; 2022; 12():1060006. PubMed ID: 36591482
[TBL] [Abstract][Full Text] [Related]
6. The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer.
Nie X; Xu T; Zhang L; Cheng W
Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():97-104. PubMed ID: 38219610
[TBL] [Abstract][Full Text] [Related]
7. Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis developed after ovarian cancer cytoreduction surgery: a case report and literature review.
Huang Y; Zhou M; Zhou J; Wu B; Yang X; Min W; Li Z
BMC Womens Health; 2023 Sep; 23(1):507. PubMed ID: 37735388
[TBL] [Abstract][Full Text] [Related]
8. Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis.
Gaba F; Blyuss O; Chandrasekaran D; Bizzarri N; Refky B; Barton D; Ind T; Nobbenhuis M; Butler J; Heath O; Jeyarajah A; Brockbank E; Lawrence A; Manchanda R; Dilley J; Phadnis S; On Behalf Of The Go Soar Collaborative
Diagnostics (Basel); 2023 Nov; 13(22):. PubMed ID: 37998621
[TBL] [Abstract][Full Text] [Related]
9. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
Zhang B; Zhou F; Hong J; Ng DM; Yang T; Zhou X; Jin J; Zhou F; Chen P; Xu Y
World J Surg Oncol; 2021 Jun; 19(1):182. PubMed ID: 34154596
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer].
Zeng J; Li N; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):401-407. PubMed ID: 34154315
[No Abstract] [Full Text] [Related]
11. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
13. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
14. [Factors affecting long-term survival of advanced high-grade serous ovarian cancer].
Shen YM; Jin LQ; Tang SS; Wang Y; Lyu WG; Chen ZB; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):393-400. PubMed ID: 34154314
[No Abstract] [Full Text] [Related]
15. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
Zou RY; Yuan L; Chen M; Yao LQ
Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
[No Abstract] [Full Text] [Related]
16. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
